Jacqueline Barrientos, MD, MS, discusses the role of non-covalent BTK inhibitors in R/R CLL and provided concise comments on the latest data, including insights from the ongoing BRUIN and Bellwave trials.
Pellini Discusses Immunotherapies and Current Limitations of ctDNA in Perioperative NSCLC
Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer
Avutometinib Plus Defactinib Signals Changing Tides in Low-Grade Serous Ovarian Cancer
Revisit the OncLive On Air Episodes From February 2024
Awareness and Early Detection Remain Key Issues in Ovarian Cancer
Naumann Spotlights Expanding Arsenals and Evolving Decision-Making in Platinum-Resistant Ovarian Cancer
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer
T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer
Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer
Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer